CV Therapeutics Seeks Ranexa Labeling Changes Based on MERLIN Study
sNDA includes new analysis of MERLIN-TIMI 36 data, which should eliminate safety concerns around QTc prolongation, clinical researchers report at the European Society of Cardiology.
sNDA includes new analysis of MERLIN-TIMI 36 data, which should eliminate safety concerns around QTc prolongation, clinical researchers report at the European Society of Cardiology.